Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

D. E. Reece; C. Bredeson; W. S. Pérez; S. Jagannath; M. J. Zhang; K. K. Ballen; G. J. Elfenbein; C. O. Freytes; R. P. Gale; M. A. Gertz; J. Gibson; S. A. Giralt; A. Keating; R. A. Kyle; D. Maharaj; D. Marcellus; P. L. McCarthy; G. A. Milone; S. D. Nimer; S. Pavlovsky; L. B. To; D. J. Weisdorf; P. H. Wiernik; J. R. Wingard; D. H. Vesole

doi:10.1038/sj.bmt.1704288

Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

D. E. Reece, C. Bredeson, W. S. Pérez, S. Jagannath, M. J. Zhang, K. K. Ballen, G. J. Elfenbein, C. O. Freytes, R. P. Gale, M. A. Gertz, J. Gibson, S. A. Giralt, A. Keating, R. A. Kyle, D. Maharaj, D. Marcellus, P. L. McCarthy, G. A. Milone, S. D. Nimer, S. PavlovskyL. B. To, D. J. Weisdorf, P. H. Wiernik, J. R. Wingard, D. H. Vesole

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Abstract

The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

Original language	English (US)
Pages (from-to)	1135-1143
Number of pages	9
Journal	Bone marrow transplantation
Volume	32
Issue number	12
DOIs	https://doi.org/10.1038/sj.bmt.1704288
State	Published - Dec 2003

Bibliographical note

Funding Information:
Genentech, Inc.; GlaxoSmithKline, Inc.; Human Genome Sciences; ICN Pharmaceuticals, Inc.; IDEC Pharmaceuticals Corporation; IntraBiotics Pharmaceuticals; Kettering Family Foundation; Kirin Brewery Company; Robert J Kleberg, Jr and Helen C Kleberg Foundation; LifeTrac/Allianz; Eli Lilly and Company; The Liposome Company; Nada and Herbert P Mahler Charities; Market Certitude, LLC; Mayer Ventures; MedImmune, Inc.; Merck & Co., Inc.; Milliman & Robertson, Inc.; Milstein Family Foundation; The Greater Milwaukee Foundation/Elsa Schoeneich Research Fund; NeoRx; Nexell Therapeutics; Novartis Pharmaceuticals; Orphan Medical; Ortho Biotech, Inc.; John Oster Family Foundation; Osiris Therapeutics, Inc.; Pfizer US Pharmaceuticals; Pharmacia Corporation; Pharmametrics GmbH; Principal Life Insurance Company; Protein Design Labs, Inc.; Response Oncology, Inc.; RGK Foundation; Roche Laboratories, Inc.; SangStat; Schering AG; Schering Oncology/Biotech; Stackner Family Foundation; The Starr Foundation; SuperGen, Inc.; TheraTechnologies, Inc.; Unicare Life & Health Insurance; Wyeth/Genetics Institute and ZymoGenetics, Inc. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Keywords

Autologous transplantation
Multiple myeloma
Older patients

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/sj.bmt.1704288

Find It

Find It at U of M Libraries

Cite this

Reece, D. E., Bredeson, C., Pérez, W. S., Jagannath, S., Zhang, M. J., Ballen, K. K., Elfenbein, G. J., Freytes, C. O., Gale, R. P., Gertz, M. A., Gibson, J., Giralt, S. A., Keating, A., Kyle, R. A., Maharaj, D., Marcellus, D., McCarthy, P. L., Milone, G. A., Nimer, S. D., ... Vesole, D. H. (2003). Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone marrow transplantation, 32(12), 1135-1143. https://doi.org/10.1038/sj.bmt.1704288

Reece, DE, Bredeson, C, Pérez, WS, Jagannath, S, Zhang, MJ, Ballen, KK, Elfenbein, GJ, Freytes, CO, Gale, RP, Gertz, MA, Gibson, J, Giralt, SA, Keating, A, Kyle, RA, Maharaj, D, Marcellus, D, McCarthy, PL, Milone, GA, Nimer, SD, Pavlovsky, S, To, LB, Weisdorf, DJ, Wiernik, PH, Wingard, JR & Vesole, DH 2003, 'Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age', Bone marrow transplantation, vol. 32, no. 12, pp. 1135-1143. https://doi.org/10.1038/sj.bmt.1704288

@article{a955687dd82a4a4ebcf265f430269466,

title = "Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age",

abstract = "The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.",

keywords = "Autologous transplantation, Multiple myeloma, Older patients",

author = "Reece, {D. E.} and C. Bredeson and P{\'e}rez, {W. S.} and S. Jagannath and Zhang, {M. J.} and Ballen, {K. K.} and Elfenbein, {G. J.} and Freytes, {C. O.} and Gale, {R. P.} and Gertz, {M. A.} and J. Gibson and Giralt, {S. A.} and A. Keating and Kyle, {R. A.} and D. Maharaj and D. Marcellus and McCarthy, {P. L.} and Milone, {G. A.} and Nimer, {S. D.} and S. Pavlovsky and To, {L. B.} and Weisdorf, {D. J.} and Wiernik, {P. H.} and Wingard, {J. R.} and Vesole, {D. H.}",

note = "Funding Information: Genentech, Inc.; GlaxoSmithKline, Inc.; Human Genome Sciences; ICN Pharmaceuticals, Inc.; IDEC Pharmaceuticals Corporation; IntraBiotics Pharmaceuticals; Kettering Family Foundation; Kirin Brewery Company; Robert J Kleberg, Jr and Helen C Kleberg Foundation; LifeTrac/Allianz; Eli Lilly and Company; The Liposome Company; Nada and Herbert P Mahler Charities; Market Certitude, LLC; Mayer Ventures; MedImmune, Inc.; Merck & Co., Inc.; Milliman & Robertson, Inc.; Milstein Family Foundation; The Greater Milwaukee Foundation/Elsa Schoeneich Research Fund; NeoRx; Nexell Therapeutics; Novartis Pharmaceuticals; Orphan Medical; Ortho Biotech, Inc.; John Oster Family Foundation; Osiris Therapeutics, Inc.; Pfizer US Pharmaceuticals; Pharmacia Corporation; Pharmametrics GmbH; Principal Life Insurance Company; Protein Design Labs, Inc.; Response Oncology, Inc.; RGK Foundation; Roche Laboratories, Inc.; SangStat; Schering AG; Schering Oncology/Biotech; Stackner Family Foundation; The Starr Foundation; SuperGen, Inc.; TheraTechnologies, Inc.; Unicare Life & Health Insurance; Wyeth/Genetics Institute and ZymoGenetics, Inc. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.",

year = "2003",

month = dec,

doi = "10.1038/sj.bmt.1704288",

language = "English (US)",

volume = "32",

pages = "1135--1143",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

AU - Reece, D. E.

AU - Bredeson, C.

AU - Pérez, W. S.

AU - Jagannath, S.

AU - Zhang, M. J.

AU - Ballen, K. K.

AU - Elfenbein, G. J.

AU - Freytes, C. O.

AU - Gale, R. P.

AU - Gertz, M. A.

AU - Gibson, J.

AU - Giralt, S. A.

AU - Keating, A.

AU - Kyle, R. A.

AU - Maharaj, D.

AU - Marcellus, D.

AU - McCarthy, P. L.

AU - Milone, G. A.

AU - Nimer, S. D.

AU - Pavlovsky, S.

AU - To, L. B.

AU - Weisdorf, D. J.

AU - Wiernik, P. H.

AU - Wingard, J. R.

AU - Vesole, D. H.

N1 - Funding Information: Genentech, Inc.; GlaxoSmithKline, Inc.; Human Genome Sciences; ICN Pharmaceuticals, Inc.; IDEC Pharmaceuticals Corporation; IntraBiotics Pharmaceuticals; Kettering Family Foundation; Kirin Brewery Company; Robert J Kleberg, Jr and Helen C Kleberg Foundation; LifeTrac/Allianz; Eli Lilly and Company; The Liposome Company; Nada and Herbert P Mahler Charities; Market Certitude, LLC; Mayer Ventures; MedImmune, Inc.; Merck & Co., Inc.; Milliman & Robertson, Inc.; Milstein Family Foundation; The Greater Milwaukee Foundation/Elsa Schoeneich Research Fund; NeoRx; Nexell Therapeutics; Novartis Pharmaceuticals; Orphan Medical; Ortho Biotech, Inc.; John Oster Family Foundation; Osiris Therapeutics, Inc.; Pfizer US Pharmaceuticals; Pharmacia Corporation; Pharmametrics GmbH; Principal Life Insurance Company; Protein Design Labs, Inc.; Response Oncology, Inc.; RGK Foundation; Roche Laboratories, Inc.; SangStat; Schering AG; Schering Oncology/Biotech; Stackner Family Foundation; The Starr Foundation; SuperGen, Inc.; TheraTechnologies, Inc.; Unicare Life & Health Insurance; Wyeth/Genetics Institute and ZymoGenetics, Inc. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2003/12

Y1 - 2003/12

N2 - The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

AB - The role of autologous stem cell transplantation (AuSCT) in older multiple myeloma patients is unclear. Using data from the Autologous Blood and Marrow Transplant Registry, we compared the outcome of 110 patients ≥the age of 60 (median 63; range 60-73) years, undergoing AuSCT with that of 382 patients <60 (median 52; range 30-59) years. The two groups were similar except that older patients had a higher β2-microglobulin level at diagnosis (P=0.016) and fewer had lytic lesions (P=0.007). Day 100 mortality was 6% (95% confidence interval 4-9) and 1-year treatment-related mortality (TRM) was 9% (6-13) in patients <60 years, compared with 5% (2-10) and 8% (4-14), respectively, in patients ≥60 years. The relapse rate, progression-free survival (PFS) and overall survival (OS) in the two groups were also similar. Multivariate analysis of all patients identified only an interval from diagnosis to AuSCT > 12 months and the use of two prior chemotherapy regimens within 6 months of AuSCT as adverse prognostic factors. Our results indicate that AuSCT can be safely performed in selected older patients: the best results were observed in patients undergoing AuSCT relatively early in their disease course.

KW - Autologous transplantation

KW - Multiple myeloma

KW - Older patients

UR - http://www.scopus.com/inward/record.url?scp=0346496578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346496578&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704288

DO - 10.1038/sj.bmt.1704288

M3 - Article

C2 - 14647267

AN - SCOPUS:0346496578

SN - 0268-3369

VL - 32

SP - 1135

EP - 1143

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 12

ER -

Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this